These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11784701)

  • 1. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease.
    Clifford JJ; Drago J; Natoli AL; Wong JY; Kinsella A; Waddington JL; Vaddadi KS
    Neuroscience; 2002; 109(1):81-8. PubMed ID: 11784701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Essential fatty acids in Huntington's disease.
    Das UN; Vaddadi KS
    Nutrition; 2004 Oct; 20(10):942-7. PubMed ID: 15474886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic administration of Congo red does not improve motor or cognitive function in R6/2 mice.
    Wood NI; Pallier PN; Wanderer J; Morton AJ
    Neurobiol Dis; 2007 Feb; 25(2):342-53. PubMed ID: 17095235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoic acid improves survival in transgenic mouse models of Huntington's disease.
    Andreassen OA; Ferrante RJ; Dedeoglu A; Beal MF
    Neuroreport; 2001 Oct; 12(15):3371-3. PubMed ID: 11711888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longitudinal analysis of the electroencephalogram and sleep phenotype in the R6/2 mouse model of Huntington's disease.
    Fisher SP; Black SW; Schwartz MD; Wilk AJ; Chen TM; Lincoln WU; Liu HW; Kilduff TS; Morairty SR
    Brain; 2013 Jul; 136(Pt 7):2159-72. PubMed ID: 23801738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease.
    Dufour BD; McBride JL
    Exp Neurol; 2016 Sep; 283(Pt A):308-17. PubMed ID: 27381424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral treatment with the herbal formula B401 protects against aging-dependent neurodegeneration by attenuating oxidative stress and apoptosis in the brain of R6/2 mice.
    Wang SE; Lin CL; Hsu CH; Sheu SJ; Wu CH
    Clin Interv Aging; 2015; 10():1825-37. PubMed ID: 26609226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of dopamine in motor symptoms in the R6/2 transgenic mouse model of Huntington's disease.
    Hickey MA; Reynolds GP; Morton AJ
    J Neurochem; 2002 Apr; 81(1):46-59. PubMed ID: 12067237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
    Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
    Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early exploratory behavior abnormalities in R6/1 Huntington's disease transgenic mice.
    Bolivar VJ; Manley K; Messer A
    Brain Res; 2004 Apr; 1005(1-2):29-35. PubMed ID: 15044061
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
    Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
    Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and behavioral analysis of the R6/1 Huntington's disease transgenic mouse.
    Naver B; Stub C; Møller M; Fenger K; Hansen AK; Hasholt L; Sørensen SA
    Neuroscience; 2003; 122(4):1049-57. PubMed ID: 14643771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cystamine increases L-cysteine levels in Huntington's disease transgenic mouse brain and in a PC12 model of polyglutamine aggregation.
    Fox JH; Barber DS; Singh B; Zucker B; Swindell MK; Norflus F; Buzescu R; Chopra R; Ferrante RJ; Kazantsev A; Hersch SM
    J Neurochem; 2004 Oct; 91(2):413-22. PubMed ID: 15447674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitochondrial calcium uptake capacity as a therapeutic target in the R6/2 mouse model of Huntington's disease.
    Perry GM; Tallaksen-Greene S; Kumar A; Heng MY; Kneynsberg A; van Groen T; Detloff PJ; Albin RL; Lesort M
    Hum Mol Genet; 2010 Sep; 19(17):3354-71. PubMed ID: 20558522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The HDAC inhibitor 4b ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice.
    Thomas EA; Coppola G; Desplats PA; Tang B; Soragni E; Burnett R; Gao F; Fitzgerald KM; Borok JF; Herman D; Geschwind DH; Gottesfeld JM
    Proc Natl Acad Sci U S A; 2008 Oct; 105(40):15564-9. PubMed ID: 18829438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased survival and neuroprotective effects of BN82451 in a transgenic mouse model of Huntington's disease.
    Klivenyi P; Ferrante RJ; Gardian G; Browne S; Chabrier PE; Beal MF
    J Neurochem; 2003 Jul; 86(1):267-72. PubMed ID: 12807446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
    Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
    Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice.
    Stack EC; Kubilus JK; Smith K; Cormier K; Del Signore SJ; Guelin E; Ryu H; Hersch SM; Ferrante RJ
    J Comp Neurol; 2005 Oct; 490(4):354-70. PubMed ID: 16127709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overexpression of heat shock protein 70 in R6/2 Huntington's disease mice has only modest effects on disease progression.
    Hansson O; Nylandsted J; Castilho RF; Leist M; Jäättelä M; Brundin P
    Brain Res; 2003 Apr; 970(1-2):47-57. PubMed ID: 12706247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease.
    Gil JM; Rego AC
    Brain Res Rev; 2009 Mar; 59(2):410-31. PubMed ID: 19118572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.